ACE and COVID-19: Studies examining the association between renin–angiotensin system inhibitor use and COVID-19 susceptibility have since been published that report no COVID-19 risk or a lower risk associated with use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).